Review of 2008: Next-gen DESs bid to upset the status quo
This article was originally published in Clinica
In 2008, two new drug-eluting stents (DESs) were launched onto the US market, making a total of four different products available to US-based cardiologists. The launches of these devices – Medtronic's Endeavor in February and, in July, Abbott's Xience V – came as confirmation, if it were needed, of the cardinal significance of DES technology. Up-and-coming firms, unable to challenge standard DESs, are aiming to displace these entrenched products by making them technologically obsolete.